Most Recent
Court orders Macquarie to pay $35M in ASIC’s short-sale reporting case
A court has ordered Macquarie Securities to pay an agreed $35 million penalty after finding that “serious deficiencies" in its reporting systems resulted in repeated failures to accurately report short sales.
AMP says insurance class action pleading ‘not good enough’
A class action against AMP over allegedly inflated insurance premiums has been ordered to better particularise its case, with a judge hearing the current pleading is "not good enough" for the wealth manager to put on a defence.
Class action against CMC Markets can add personal advice claim
A class action against CMC Markets got the go-ahead Thursday to add new claims in its case centred on risky financial products, after trawling through 27,000 documents produced by the trading platform.
Court upholds IAG’s privilege claim in ASIC discounts case
A judge has upheld IAG’s privilege claim over a technical paper prepared by an actuarial consultant, finding that the report was not merely forwarded to the legal team to cloak it in privilege. 
CBA to file cross-appeal with High Court in shareholder class actions
CBA plans to file a cross-appeal in the class actions before the High Court, contending the shareholders -- who argue they should have won their loss case -- failed to establish disclosure breaches at the threshold.
ASIC fights IAG’s privilege claim in loyalty discounts suit
The corporate regulator is challenging insurer IAG's claims of legal professional privilege over a technical report in proceedings over allegedly misleading loyalty discounts.
Takeovers Panel says Cosette can’t shutter Mayne’s Adelaide drug plant
The Takeovers Panel has found Cosette cannot close a Mayne Pharma drug manufacturing plant in Adelaide, another win for Mayne in its push to block the US drug maker from walking away from their $672 million merger.
Mayne wins extension of FIRB deadline for Cosette takeover
The Foreign Investment Review Board has extended the deadline for ruling on Cosette's proposed $672 million takeover of Mayne Pharma.
Mayne, Cosette row to be decided on merits after panel resets merger clock
The Takeovers Panel has agreed to hear Mayne Pharma's latest dispute with Cosette over the US drug maker's attempts to walk away from their $672 million merger agreement and extended the timeline for completing the deal.
Mayne wins breathing room in fight to get Cosette merger over the line
Mayne Pharma has secured an extension of the deadline for securing Foreign Investment Review Board approval of its $672 million tie-up with US drug maker Cosette.